Hear from Formation Bio co-founder & CEO Benjamine Liu on the Inside the ICE House podcast where he talks about... - Bottleneck's slowing down drug development - AI's impact on drug discovery - Bringing new medicines to patients Spotify: https://lnkd.in/gA-NiPcj YouTube: https://lnkd.in/gFDewkV8
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development
100% agree Benjamine Liu. Supply demand economics will greatly devalue preclinical assets given the multiple X increase in AI generated assets .. unless there is a way to scale conviction that the asset(s) have value in development stages (especially phase 2, where attrition is ~ 70%). Great points.